<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9585">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05694975</url>
  </required_header>
  <id_info>
    <org_study_id>2023-KY-001-02</org_study_id>
    <nct_id>NCT05694975</nct_id>
  </id_info>
  <brief_title>Efficacy of Megadose Vitamin C in Severe and Critical Ill COVID-19 Patients.</brief_title>
  <official_title>Clinical Efficacy of Megadose Vitamin C in Severe and Critical Ill COVID-19 Patients (CEMVISCC): A Multicenter, Randomized, Single-blind, Placebo-controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhujiang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhujiang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main aim is to determine whether vitamin C can reduce 28-day all-cause mortality or&#xD;
      persistent organ dysfunction compared with placebo in patients with severe and critical ill&#xD;
      COVID-19 patients.&#xD;
&#xD;
      Participants will randomly receive HIVC or placebo for 4 days once enrolled. The primary&#xD;
      outcome is a composite of death or persistent organ dysfunction (defined as dependency on&#xD;
      vasopressors, mechanical ventilation, or CRRT) at day 28 after randomization.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 13, 2023</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A prospective, multi-center, randomized, single-blind, placebo-controlled clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The 28-day mortality or persistent organ dysfunctionat day 28.</measure>
    <time_frame>28 days.</time_frame>
    <description>Persistent organ dysfunction was defined as dependency on vasopressors, mechanical ventilation, or new and persisting RRT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the Sepsis-Related Organ Failure Assessment (SOFA) score.</measure>
    <time_frame>4 days.</time_frame>
    <description>The SOFA score range from 0 (mild) to 24 (critical ill). Change = (Day 4 score - Baseline score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma Inflammatory Biomarker Concentrations.</measure>
    <time_frame>4 days.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in oxygenation index and partial pressure of carbon dioxide in arterial blood gases.</measure>
    <time_frame>4 days.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The duration of ventilation and vasopressor use.</measure>
    <time_frame>28 days.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The length of ICU stay and hospital stay.</measure>
    <time_frame>28 days.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">608</enrollment>
  <condition>Vitamin C</condition>
  <condition>COVID-19 Pneumonia</condition>
  <arm_group>
    <arm_group_label>Vitamin C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 g Vitamin C will be infused within 6 hours by an infusion pump. This treatment will be repeated every 12 hours for 4 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The control group is assigned a placebo (5% glucose).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin C</intervention_name>
    <description>The total dosage of vitamin C for the treatment group is 24 g per day.</description>
    <arm_group_label>Vitamin C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The total dosage of placebo(5% glucose) for the control group is 24 g per day.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults (age 18 years or older).&#xD;
&#xD;
          2. Diagnosed with COVID-19 according to the Diagnosis and Clinical Management of&#xD;
             COVID-19. (trial version 10).&#xD;
&#xD;
          3. severe and critical ill patients with COVID-19.&#xD;
&#xD;
          4. Patients who voluntarily participate in the study and sign the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with a history of allergy to VC.&#xD;
&#xD;
          2. Pregnant or lactating women.&#xD;
&#xD;
          3. Patients with end-stage malignant tumour.&#xD;
&#xD;
          4. Patients with an expected survival duration of less than 24 hours.&#xD;
&#xD;
          5. Patients with cerebral hernia and severe craniocerebral injury.&#xD;
&#xD;
          6. Patients with diabetes.&#xD;
&#xD;
          7. Patients with a previous history of G-6-PD deficiency.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liu Zhanguo, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Southern Medical University, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liu Zhanguo, MD,PhD</last_name>
    <phone>18520711669</phone>
    <email>zhguoliu@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yu Shuang, MD</last_name>
    <phone>13476932240</phone>
    <email>yushuang7991@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Critical Care Medicine of Zhujiang Hospital</name>
      <address>
        <city>Guanzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>zhanguo Liu, M.D.PhD</last_name>
      <phone>+862062782927</phone>
      <email>zhguoliu@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yunfu People's Hospital</name>
      <address>
        <city>Yunfu</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chen Shaowu, MD</last_name>
      <phone>13322946821</phone>
      <email>13322946821@189.cn</email>
    </contact>
    <contact_backup>
      <last_name>Peng Wei, MD</last_name>
      <email>1561015010@qq.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Department of Critical Care Medicine of Zhongshan People's Hospital</name>
      <address>
        <city>Zhongshan</city>
        <state>Guangzhou</state>
        <zip>528403</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jianwei Li, MD</last_name>
      <email>likenwei@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>the Affiliated Nanhua Hospital</name>
      <address>
        <city>Hengyang</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yao Hongyi, MD</last_name>
      <phone>18773486373</phone>
      <email>32425082@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 14, 2023</study_first_submitted>
  <study_first_submitted_qc>January 19, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2023</study_first_posted>
  <last_update_submitted>January 19, 2023</last_update_submitted>
  <last_update_submitted_qc>January 19, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhujiang Hospital</investigator_affiliation>
    <investigator_full_name>Liu Zhanguo</investigator_full_name>
    <investigator_title>Clinical Efficacy of Megadose Vitamin C in Severe and Critical Ill COVID-19 Patients (CEMVISCC): A Multicenter, Randomized, Single-blind, Placebo-controlled Clinical Trial</investigator_title>
  </responsible_party>
  <keyword>Vitamin C</keyword>
  <keyword>COVID-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

